Report Code: A12601 | Nov 2023 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Relapsing-remitting Multiple Sclerosis Market
Request Now !Relapsing-remitting multiple sclerosis (RRMS) is a kind of multiple sclerosis. It is the most common type of multiple sclerosis (MS), accounting for around 85% of source of diagnoses. Relapses of MS occur in people with RRMS with periods of remission occurring in between. MS is a chronic, progressive condition of the central nervous system (CNS) in which your immune system attacks myelin, the protective layer around nerve fibers. Damage of the myelin causes the nerves inflammation, which makes it difficult for your brain to connect with the rest of your body.
The specific causes of RRMS and other types of MS is currently unknown. A combination of genetic and environmental factors, such as smoking, vitamin D deficiency, and certain viral infections, may all play a role. Although there is no cure for MS, Â but treatment can help manage symptoms, treat relapses, and slow down the progression of the condition. A variety of medications and therapies are available. For example, medications can help with symptoms like fatigue and muscle stiffness. A physiotherapist can assist with mobility difficulties or muscle weakness.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that first emerged in late December in the Hubei province of the Wuhan city in China. The virus that causes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Â is highly infectious and, is transmitted from person to person. Since the outbreak in December 2019, The disease has spread to almost 213 countries across the globe with the World Health Organization to declare it a pandemic on March 11, 2020.
Coronavirus disease 2019 (COVID-19) has caused an economic crisis along with the healthcare crisis. The COVID-19 pandemic has stretched the global healthcare system, and  developed countries are anticipated to experience an economic recession as a result. The pandemic has had an adverse impact on the healthcare system, with revenue dropping by a 50% to 70% drop since March. Several small hospitals, clinics, and nursing homes have been forced to shut their operations Furthermore, social distancing and localized curfews have resulted in delayed elective surgical procedures. Moreover, visa cancellations have disrupted medical tourism which can negatively impact the growth of relapsing-remitting multiple sclerosis market.
During the spread of the pandemic, however, the testing scale has increased, allowing for data sharing and provides reliable lab results.
Top Impacting Factors
An increase in the geriatric population is driving the growth of the global relapsing-remitting multiple sclerosis market. According to a recent study, one in every six people in the world would be 65 and older by the end of 2050. The situation is more pronounced in Europe and North America where one in every four people will be affected. Already in 2018 the population of this age group has surpassed that of children aged 5 and under. This Increase in geriatric population will need healthcare facilities, which is expected to enhance growth of the  relapsing-remitting multiple sclerosis market.
The cost of drugs remains a major challenge for the growth of the market due to increased government interventions and various treatment options for multiple sclerosis. However, patent expiry of major drugs is key restraint of the global MS drugs market. Furthermore, stringent regulatory constraints restrict the growth of the global MS drugs market.
Key Market Trends
Monoclonal antibodies are now being increasingly employed for the treatment of RRMS. Many clinical trials are focused on novel drugs using antibodies. There is an increase in the demand for immunosuppressive drugs for treating this condition..
F. Hoffman-La Roche Ltd., launched Ocrevus in 2017, and it soon became one of the blockbusters profits -making drug.
Key Benefits of the Report
Questions Answered in the Adenovirus Diagnostic Testing Report
Relapsing-Remitting Multiple Sclerosis Market Report Highlights
Aspects | Details |
---|---|
By Treatment |
|
By Route of Administration |
|
By End User |
|
By Region |
|
Key Market Players | GlaxoSmithKline, Pfizer, Inc., Biogen, Novartis, Teva Pharmaceutical Industries Ltd., Bayer HealthCare, Acorda Therapeutics Inc., Sanofi, Merck and Co., Inc., Roche |
Start reading.
This Report and over 66,965+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers